Good morning.
Futures rolling over — S&P red, Dow -200, chips dragging the Nasdaq. De-grossing day two, and the macro leg just got worse: Brent >$92, diesel crack >$100, and now the LONG END is moving — BUND 10Y 3.339%, HIGHEST SINCE 2011, JGB 30Y AT HIGHS. Front-end moves price policy path; long-end moves inflation risk premium — that hits AI duration first.
Zhipu 1H mixed, but ARR is the tell: August ARR exceeded all of 1H, inference cost -80%, token consumption +40x. Jevons-positive for the whole stack, though 100k domestic accelerators in production inference is a slow bleed for NVDA's China TAM. MediaTek LIMIT-UP to NT$4,315 on the NVDA/GOOG $3.9B convertible — market re-rating 2454 as NVDA ecosystem equity, not a phone SoC. NVDA soft: Barron's slapped the $35B Anthropic/Lambda deal "most confusing yet," and circular financing is now a priced factor, not just a sell-side worry.
Macro: eurozone inflation >3% locks an ECB hike; Bessent jawboning Japan. Coordinated global duration shock.
Three themes. One: long-end inflation premium vs crowded AI longs — rates are doing the de-grossing for us. Two: pricing power up the stack — NVDA warning 15% AI server price hikes, TSMC eyeing 10-15% across all nodes, Korea flash ASP +63% M/M. Three: memory goes custom — SK Hynix 5.15x inference claims, Samsung HBM5 at 2x HBM4E, PIM finally has production dates. SEMICON Taiwan opens tomorrow; the whole industry answered NVHBM inside two weeks — that's a toll booth, not a coincidence.
Micron's Taiwan union strike threat is un-priced operational risk landing right on DRAM tightness. Watch the vote.
We'll hit up NVDA, INTC, and 2454 first, then get to the memory complex and the SEMICON Taiwan story.
Verdict: Earnings land tomorrow, the stock's up ~97% in six months, and every bull on the street is holding the same hand. The analyst community isn't debating whether Q2 beats — they're debating how much of the AI consumption story is already in the tape. Six firms moved in the last 72 hours, all pointing at the same setup: clean channel checks, beat-and-raise expectations, and a product cycle that finally has teeth.
Snowflake prints FQ2 (July quarter) after the close on September 2. Stock sits at $331.43, a hair under the $341.95 52-week high. Options market's pricing a 12% post-earnings move — that's not a coin flip, that's the market bracing for something binary.
Rosenblatt's checks say product revenue lands marginally above ~31% YoY organic growth (Q1 printed ~34%). Cantor models a >3% beat vs. guidance midpoint, down from 5.5% last quarter. So yes — beat, but the beat magnitude is normalizing. That's the single most important datapoint in this setup. 31% LTM revenue growth, 67% gross margin, Q1 delivered a ~5% beat. The base business is fine.
Five firms raised/reiterated into the print, and the PT cluster tells the story:
Cantor's checks show Cortex Code adoption stayed strong through Q2 with core usage robust. But the crux of the debate — and the line that matters most going into the print:
"A key focus will be whether incremental AI consumption can more than offset any possible optimizations related to consolidations and expectations of strong renewals."
That's the whole ballgame.
Bull: The migration story compounds, AI products add a second growth vector on top of it, and the beat-and-raise cadence continues. Rosenblatt's rolling FY29 estimates into the model signals multi-year visibility, not a one-quarter story. Gross margin holds at 67% while growth stays above 30% — that's a scarce combo in software right now.
Bear: The stock's already done the work. +97% in six months. One of the biggest software multiple expansions of the year. MS's $300 PT below the current price and Guggenheim's Neutral are the tell — there are grown-ups who think this is priced for perfection. If AI consumption merely offsets optimization headwinds instead of layering on top, the "beat" lands as a "sell the news" moment. A 12% implied move cuts both ways.
Setup is clean: beat, raise, AI narrative intact, channel checks green. The risk isn't the quarter — it's the positioning. Everyone's on the same side of the boat, and the boat's already sailed ~100% in six months. PMs should key on management's commentary on AI consumption vs. optimization/consolidation drags, not the headline number. If they frame AI as incremental and net-additive, $345-370 holds. If they hedge it as "offsetting," this prints a volatility event at a bad price.
Piper Sandler re-ups Overweight and $320 PT on a simple, clean thesis: Amazon prints the most consistent ROIC in big tech. (17% avg 2018-2025, 12% LTM, 14% projected 2026.) At 21.34x P/E with a PEG OF 0.24, you're paying almost nothing for that compounding. The valuation hook does the heavy lifting here.
The real signal is the capex divergence. Piper flags ROIC DETERIORATION AT META (-27PP) AND ALPHABET (-26PP) from 2024-2027 — those guys are torching cash on frontier models. Amazon points its capex at AWS, and Jassy runs an explicit ROI framework with payback periods. Same war, different playbook — and Amazon's is the one with the rate-of-change kicker.
"Amazon shows the most consistency in return on invested capital among major technology companies."
Satellite news: AWS grabs DuckLabs (DuckDB) for the analytics stack — smart bolt-on. Sweden wind PPAs add ~200MW now, 1GW+ at full run. Evercore raises to $355 off Alexa AI purchase data (57% of users bought items they didn't know existed). Citizens holds at $315.
Bull case is plain: best capital allocator in the group, cheapest growth-adjusted multiple. Bear case is AWS decel — nothing in this note argues that.
Cantor's holding Neutral with a $100 PT into a 20% weekly rip, and the stock's at $96.75 — right under the $108 high. The bull case is real: total revenue accelerated to 15%, sales-led sub to 17% in cc, cRPO grew 20%+ cc for the SECOND STRAIGHT QUARTER, RPO up 27%, consumption accelerated QoQ. FY27 guidance calls for further reacceleration. The bear case lives in the Q2 guide — sales-led sub implies FLAT QoQ — and NRR drifting to 111% from 112% says expansion is cooling even if new logos aren't.
Piper's the bull at $130, Canaccord $120, DA Davidson and Cantor both at $100. 15 analysts revised up. At $1.8B LTM with a 75.6% gross margin and 27x P/E, you're paying up and the multiple is justified only if cRPO keeps compounding.
"Committed remaining performance obligations sustained growth above 20% in constant currency for a second consecutive quarter. Remaining performance obligations grew 27%."
That's the number that matters. If it holds, flat Q2 is phasing noise. If it rolls over, Needham's Hold and Cantor's Neutral look smart.
Entire Street on one side into the Sept 8 print. TD Cowen reiterates Buy/$125 with the stock at $98.04 — call it ~27% upside. Consensus is 1.41 Strong Buy, PTs clustered from BMO's $103 to Cowen/Stifel's $125.
Weather plus AI. JULY RAN +2% YOY — HOTTEST MONTH ON RECORD — and TD Cowen's HVAC checks show a monster summer even against last year's refrigerant-change comp. That sets up the seasonally strongest quarter, with Max and Virtual Agents as the adoption accelerant. Stifel's the most aggressive: modeling revenue ~5pp above the historical range and FY27 guidance in the low-20s%. At a $9.35B market cap, that's the whole re-rating debate in one number.
"expecting ServiceTitan to exceed its historical revenue range by approximately 5 percentage points and projecting fiscal 2027 guidance to be in the low-20s percentage range."
Everyone's long — BMO, Truist at $110, Piper at $115, KeyBanc at $120, Cowen/Stifel at $125. When positioning's this uniform, the risk isn't the print, it's the guide. Hot summer bakes Q2; the question is whether 20%+ FY27 is already owned. Max metrics show up and this re-rates. Guide lands at 20% or below and the crowded long gets ugly. Not reading much into the platform's "overvalued on fair value" call — at 1.41 consensus, everyone knows it's priced for perfection.
B.Riley starts GRRR at Buy, PT $25 — stock at $14.95, so 67% upside if you trust the backlog. This is a contracted-AI-infrastructure story trading like a pre-revenue hardware name.
THE PITCH: $5B+ in signed AI backlog across Yotta (India) and NeutraDC (Indonesia). FY26 revenue guided to $200M+, FY27 to $450-500M (all firm-schedule contracted, per management). Q2 already shows the trajectory: REVENUE +138% Y/Y TO $50.1M, H1 at $78.4M (+99%). They beat raised guidance and still the stock sold off after-hours — that tells you exactly what the market fears.
The valuation is the tell. GRRR trades at 0.9x 2027E EBITDA vs 7.0x peer average. That's not a discount, that's a statement. B.Riley pins it on three bogeys: GPU deployment execution risk, open project financing, and the convertible dilution overhang. Fair. They expect those to de-risk through 2H26-27 as higher-margin take-or-pay GPUaaS revenue starts hitting the P&L.
"The market is pricing the company on its compressed near-term margins and convertible dilution overhang while under-crediting the contracted backlog and owned-capacity optionality at Korat."
The bear case is real — this is capex-heavy, financing-dependent, and the after-hours reaction to a blowout quarter says investors aren't buying the roadmap yet. But the backlog is contracted, not aspirational. At 0.9x forward EBITDA with take-or-pay revenue coming, the r/r here is genuinely skewed. Cheap for a reason, but the reason is timing, not demand.
Truist is the bull here, and they're leaning in. Raised PT to $40 from $35 after a sit-down with CEO Mathradas, CFO Lee and IR Righetti — sees FIVN becoming a "humantic interaction layer" stitching humans and AI agents together. Stock's at $33.21, up nearly 96% over six months and pressing the 52-week high of $35.17. The r/r still works if you buy the AI narrative.
"Humantic interaction layer" — that's the pitch. Truist walked away with increased confidence that positive fundamental trends continue, and slaps "deep value levels" on the multiple.
The numbers back the story: Q2 printed $0.70 vs $0.68 est, revenue $312.4M vs $306.4M est (+10% YoY), subscription +14%, and AI revenue SURGED 78% TO ~$39M. That AI line is the whole thesis — small but compounding fast. Rosenblatt and DA Davidson both bumped PTs too ($32 and $28), though Davidson stays Neutral — the AI acceleration is real, they're just not ready to pay up.
Bear case isn't dead. Margins are under pressure and management's profit outlook is cautious — that's why this trades at 1.9x EV/sales and 12.2x EV/FCF on 2027 numbers. Cheap for a reason, or cheap because the market hasn't re-rated the AI optionality? Truist's bet is the latter. At $33 vs a $40 PT, that's ~20% upside in a name that's already run 96%. Decent r/r for a mid-cap CCaaS in the green.
KC's the cheap way to play China AI cloud. GS re-ups Buy and $18 PT into the print; stock sits at $10.24 — that's ~75% upside to the target, and the Street cluster runs $16.01-$26.37. (BofA to $21.40, Jefferies to $17.70, both Buy.) The Q2 print delivered: REVENUE RMB3.07BN (+31% YOY, beat the ~RMB3.03BN bogey) and the first positive GAAP operating profit margin, ever. That's the kind of inflection that gets PMs leaning in.
The thesis is mix shift. AI cloud revenue +82% YOY, now 43% of total per GS (the company release cites 56% — different definitions, don't chase the gap). MaaS carries the fattest gross margins inside that bucket, and management guides to stable GM/EBITDA plus positive GAAP op margin through 2H26, with positive adjusted net profit margin targeted for 2027.
"Model-as-a-Service carries the highest gross profit margin within the AI cloud segment." — Goldman's Timothy Zhao
Here's the rub: KC budgeted RMB15BN in capex for 2026 (direct procurement plus compute rental). AI IaaS payback runs 3.5 YEARS by revenue — shorter by cash flow on prepayments. Bears see a capital treadmill; bulls see a funded land-grab where mix shift to MaaS bends the margin curve up. At $10.24 against a $16-26 target cluster, the market's pricing in substantial doubt. GS is comfortable waiting for the 2027 profit proof point.
Cantor goes to $540 from $416 — street high — and the entire pre-earnings tape leans one way into tomorrow's print. Partner checks on Atlas are clean: consumption, workload adds, migrations, win rates all healthy. Cantor's real call: the implied Atlas deceleration to ~21% in 2H FY27 is conservative against FOUR STRAIGHT QUARTERS OF 29-30% GROWTH.
That's the bull case in a nutshell — guidance bogey. Management guided Atlas to 26% for FQ2; DA Davidson models 28-29%. Evercore started Outperform at $525, hammering the point that Atlas is ~75% of revenue and production AI workloads are the next leg. PTs have clustered up to $460-540 from the $416 area, all pre-earnings, all saying the guide is low.
Stock's up 41.5% and trades at $444 — about 6% off the $473 high. The setup prices in good news, not great news. UBS at $460 Neutral is the lone wet blanket: demand stable, but valuation leaves little torque. Cantor's $540 is 12x CY27 revenue, so this is a multiple-expansion bet as much as a fundamentals one.
Tomorrow's print matters less than the 2H guide. Checks say consumption is fine. The question is whether management sticks to the decel storyline or lets Atlas rip.
DA Davidson lifts PT to $45 from $35 — right at spot ($45.30). That's a catch-up move, not a conviction call. Sell-side is chasing a stock that ran 70% in six months into tomorrow's earnings print.
Four firms, $40-50 PT cluster. Cantor the bull at $50 on AI-driven platform engagement. TD Cowen $42 on developer hiring. UBS $40, Neutral, stable demand. DA Davidson $45, Neutral, consumption trends. Shared thread: consumption run-rate inflecting, but the monetization model transition muddies growth optics.
Bull case: +24% YTD vs IGV +6%. Public sector and DAP adoption upside. Other infra software names accelerated last quarter — GTLB rides that comp tailwind.
Bear case: growth decelerating through the model shift. And when a Neutral shop flags expectations as ELEVATED into the print, PMs should read the room.
"Expectations for second-quarter fiscal 2027 results are likely elevated given the acceleration of growth from other infrastructure software players."
Three of four PTs sit below spot. Only Cantor's $50 clears the tape. That's the market telling you r/r is roughly 50/50 into a binary print tomorrow after close.
Scotiabank just threw the high bid on the board — Patrick Colville bumps PANW to $430 from $320, Sector Outperform, into tonight's FQ4 print. Stock's at $382, up 157% in six months, breathing distance from the $398.88 high. This is not a value call. It's a momentum call with the multiple already at DOUBLE the five-year average EV/EBITDA (206x, with a 332x P/E). CrowdStrike's strong print last week gives the comp tailwind, and Colville's CISO checks are improving — he worked 15 investors in NY/CT this month.
The bar is the issue, not the direction:
"The company must report NGS ARR of $8.96 billion in Q4 and guide to $11.13 billion for fiscal 2027 at the midpoint for shares to remain flat."
"Remain flat." That's the tell. Perfection is the base case at this valuation — tonight is about whether FY27 guidance clears the $11.13B bogey or just kisses it. Scotiabank sees near-term r/r as a "slight positive," which is about as excited as anyone gets at 206x EV/EBITDA.
The rest of the Street ladders up behind them: Evercore at $415 (partner sentiment improving, AI security pipelines), JPMorgan at $384 (platform strength, FCF machine), BTIG at $380 (bullish channel checks), D.A. Davidson at $345 (beat-and-raise potential). Options market implies an 8.6% move tonight — and PANW has cleared the implied move in half of its last eight prints. This one's a coin flip with a massive multiple either way.
Merger's terminated. Stock's unshackled. BofA resumes at Buy, $42 PT (~18% upside from $35.54), but the street's already more aggressive — BMO holds Outperform at $50, Freedom Broker upgraded to Buy at $48. All three land in the same place: the Solstice overhang lifted and focus returns to a business that didn't need the deal anyway.
Q2 proved the point. Adjusted EBITDA $184M, +35% YoY, ~10% above consensus. Electronics did the heavy lifting: 20% organic sales growth, 47% EBITDA growth. AI infrastructure plus Kuprion keeps the engine running — BofA models high-teens EPS growth over the next two years. Six analysts just revised estimates UP. (Clean break too: no termination fees, Solstice announced a $500M buyback.)
"With the deal off, focus returns to the company's fundamentals."
Bear case? $35.54 isn't cheap if AI capex hiccups. Nobody's pressing that today. Momentum is the trade.
The real juice is the optionality. Management embedded MINIMAL AI contribution in FY27 guidance, so any agentic/non-human identity upside is unmodeled. Cantor flags a potential $8-10M organic NNARR beat and a guidance raise as the near-term catalysts. Entro Security acquisition closed — standalone non-human identity offerings plus platform integration, which gives the AI narrative more surface area.
"At approximately 9 times fiscal 2027 estimated sales, the valuation does not reflect growth opportunities in agentic artificial intelligence and non-human identities. Yet."
That "Yet" is the whole trade. Mizuho still Neutral, wants proof on the $2.1B ARR by 2029 target. Fair ask. But with AI revenue under-modeled and checks constructive, r/r skews favorable into the print.
NEEDHAM STARTS RDVT AT BUY, PT $90 — BUT THIS IS A STOCK THAT’S ALREADY UP 69% IN SIX MONTHS AND TRADING $1.60 OFF ITS 52-WEEK HIGH. The initiation is less a fresh idea and more a "get on board before the next leg" call. The thesis: Red Violet has the leading cloud-native identity intelligence platform, covers ~100% of US adults, prints 85% gross margins, and has a perfect Piotroski Score of 9. The recent capital raise gives them fuel to push brand awareness and take share from legacy competitors drowning in tech debt.
"Legacy competitors face challenges from tech debt and platform construction issues."
Still, the easy money may be made. Q2 was a beat — adjusted EPS $0.50 vs $0.33 consensus, revenue $26.7M vs $24.8M, up 23% YoY, with record EBITDA and customer adds. That’s real momentum, but at $73 with a $90 target, the r/r is decent, not spectacular. The bull case is that this is still an under-owned compounder in a fragmented market. The bear case: you’re buying a stock near highs on the back of one initiation. We lean constructive but would prefer a pullback toward $65 for better entry.
Truist's $300 PT (from $245) is the headline, but the real story is the street collectively chasing a stock that's ALREADY UP 24.6% IN A WEEK. This is catch-up, not leadership — the tape got there first and the buysiders are scrambling to mark models to reality.
The record FQ2 did the heavy lifting: ARR beat by $46M, revenue +26%, non-GAAP EPS +33.5%. But the single most important data point is net new ARR GROWTH OF 51% YOY — that's the post-Mythos acceleration print, and it's why DA Davidson, Piper, and Benchmark all joined the PT raising parade ($240-250 cluster). Argus is the outlier at $425; Bernstein's $119 Market Perform is the lonely bear.
The whole debate now is durability. Truist isn't just stamping a higher number — they're asking whether the demand acceleration supports a structurally HIGHER long-term growth framework. That's the right question. AIDR monetization, Falcon Flex expansion, and the product-level growth drivers (Identity, Cloud, SIEM) are the bogeys to watch at Fal.Con. If management shows AI is expanding the size and duration of the opportunity, this thing has room to run through the $300 PT into the $350s.
"CRWD heads into Fal.Con following a record quarter and another meaningful increase to FY27 expectations. We will primarily be looking for evidence that the post-Mythos demand acceleration can support a higher long-term growth framework, with particular focus on AIDR monetization, future net new ARR potential, product-level growth drivers and Falcon Flex expansion dynamics."
The bull case: this is a platform re-rating, not a quarter re-rating — the multiple compresses as growth accelerates. The bear case (Bernstein at $119) says the re-rating is a function of the Mythos stock recovery narrative, not real durability. That spread of $119 to $425 tells you everything about the conviction gap right now. We'll get the answer at Fal.Con.
Citi bumps ADBE to $301 from $228, but don't mistake the PT move for a fundamentals call. This is software multiple expansion doing the heavy lifting — target implies just 10.4x FY28 EV/FCF — while the rating stays Neutral and the thesis stays cautious.
The setup: Citi sees the ~$500M organic cut to FY26 total ARR guidance creating an ACHIEVABLE setup for Q3 (they nudged Q3/Q4 estimates slightly above guidance). That's damning with faint praise — even with the nudge, second-half net new ARR still declines 26%. Checks with partners and at Cannes showed zero change in enterprise buying behavior. Creative negativity persists. Only Firefly reads tick up, on capabilities and governance.
"Citi said it remains cautious on Adobe fundamentals but sees the approximately $500 million organic cut to the FY26 total ARR guidance from the prior quarter creating an achievable setup for Q3."
The real risk lives in FY27. Citi's total ARR growth estimate sits BELOW Street consensus, as the model leans more on freemium-led strategies. That's the bear case. The bull case exists — HSBC upgraded to Buy on AI-competitor resilience, CLSA started Outperform at $300, and the Saudi deal (27M users, $4B value) gives a headline catalyst. Morgan Stanley's the other side at Underweight/$240 on AI substitution risk. Three-way analyst split. Citi's middling stance is the honest one: the quarter prints, the story doesn't get easier.
Piper Sandler flips TEM to Overweight from Neutral, PT to $76 from $56 — the call isn't just the upgrade, it's the reason. The stock was previously rated Neutral because the price was being driven by AI sentiment, disconnected from the actual diagnostics/data performance. Now Piper sees three hard catalysts that close that gap: Personalis acquisition, the INTerpath-001 readout, and FDA approval of tumor-only xT CDx clearing the path to unified ADLT pricing.
"The positive INTerpath-001 readout increases the strategic value of Personalis and Tempus AI's role as the tumor sequencing provider for potentially a new therapeutic class."
That's the bull case condensed: TEM becomes an infrastructure play for a new drug class, not just another AI-adjacent story stock. 50% REVENUE GROWTH LTM helps. The xF product could follow the same regulatory path in 2H 2027 — that's the next leg.
Q2 was fine, not clean: EPS beat (-$0.04 vs -$0.08 est) but revenue $382.5M missed some bogeys ($390.9M HCW), though it was the first full Ambry quarter. Street targets range $35-$100 — that's a 3x dispersion on an $11.4B market cap. Canaccord sits at $80, BTIG at $70, Stifel at $50 on margin concerns. The bear case: this is still a diagnostics business that keeps catching AI multiple bids. Piper's upgrade says the fundamentals finally earn the multiple. The range says the market hasn't decided which one it is.
RJ keeps Outperform/107 after F3 entered service over APAC. Constellation is finally whole — F2's in final testing and should go live soon, right on the Sept timeline. Stock's DOWN 6.8% on the week despite the print (after +108% in a year, some air pocket is healthy). This isn't a satellite story anymore; it's a spin story.
F3 live means Comms Services EBITDA can start growing late calendar 2026/early 2027 (TTM: $1.39B). That's the prerequisite for the Defense & Advanced Technologies separation. Needham's at $105 Buy; Barclays is the lone holdout at $49 EW — the execution-vs-balance-sheet debate in one line. Q1 was in line ($1.2B rev) but DAT fell 4% and adj. EBITDA dropped 7% y/y. Legacy shrinking, new story loading.
Successful satellite deployments could allow Viasat to move forward in its review of a Defense & Advanced Technologies spin.
Spin announcement is the real catalyst. Everything else is noise.
UBS just re-rated the narrative, not the fundamentals. PT to $20 from $14, holding Buy, on a 30x EV/EBITDA multiple applied to 2Q28E adjusted EBITDA (was 21x). Stock trades $16.11 — basically pinned to the 52-week high of $16.22. This is pure multiple expansion, justified by nuclear fuel supply comps sitting at ~30x 2027 EV/EBITDA.
The underlying business is inflecting, but from a tiny base. Q2 REVENUE $4.7M VS $0.6M LAST YEAR — first commercial TRISO fuel delivery — and net loss narrowed to $3.4M from $7.7M sequentially. Still bleeds, still pre-profit, but directionally the right way. The $20 PT implies ~15x 2028E EBITDA, so UBS is underwriting a serious earnings ramp, not the current P&L.
"The revised 30x target multiple remains in line with the average 2027 EV/EBITDA of Standard Nuclear's nuclear fuel supply peers."
Consensus sits at 1.25 Strong Buy, targets $13-$20. At $2.5B market cap with $4.7M quarterly revenue, you're paying for nuclear fuel demand conviction and TRISO commercialization — not current earnings. The multiple's now at peer parity, so the easy comp-driven upside is gone. Next leg needs the earnings ramp to actually show up. R/r still works, but this one requires patience.
BofA goes to $600 from $500, Buy intact. Azure acceleration is the whole thesis — and the guide makes it credible, not hopium.
AZURE PRINTED 43% IN FQ4 (from 39% in FQ3) WITH A 45% GUIDE FOR FQ1'27. At this scale, that's hand-over-fist acceleration. The re-rating to 28x CY27 P/E from 24x isn't heroism — it's paying up for visible compounding.
The supporting cast matters. PAID COPILOT SEATS >30M WITH NET ADDS DOUBLING QoQ, and RPOs +84% YoY — the forward pipeline does the talking. Meta's hundreds-of-millions annual Azure AI spend confirms this is a broad landgrab, not a one-customer story.
BofA remains constructive on Microsoft's long-term positioning across AI infrastructure, models and applications.
Side noise: Nvidia scoops Hugging Face (defensive, per DA Davidson — doesn't move MSFT's moat), JMP reiterates Market Outperform on Moonshot pricing chatter, Moody's affirms Aaa. None of it shifts the setup. Stock sits at 28.5x with a 0.89 PEG, and 17 analysts already revised estimates up. Momentum and valuation still coexist — rare at $1T+.
Evercore ISI just chopped APP to $510 from $630 — still Outperform, but that's a 19% haircut on a stock already DOWN 54% YTD at $312, basically sitting on its 52-week low of $297.50. The bull case isn't dead, but it's on life support. The admission that matters: their e-commerce advertiser spend estimates through Q2 were simply too high. They cut Q4 and FY27 off the back of it.
August mobile game advertiser checks are a mixed bag — 3 of 5 contacts positive on early Q3 model enhancements, 2 calling out material lifts, 2 neutral. Evercore's concern: those lifts get harder to produce under the current Axon 2 architecture. They've now modeled FY27 on self-learning gains and seasonality only, pending Axon 3 — which they think lands within 12 months.
The firm said it now believes its estimates of historical e-commerce advertiser spending through the second quarter were too high.
One more wrinkle from Evercore: increased brand utilization of mobile in-app inventory could raise clearing prices and mute take rate accretion — so even a healthy ad market doesn't automatically translate to model lifts.
The rest of the Street has already piled out. BofA downgraded to Neutral ($400 PT, from $430) on long-term revenue sustainability. BTIG went to $408 from $574 after the commerce strategy shift and weak Q2 gaming. Benchmark cut to $440, Needham to $475, Piper Sandler down to $325 at Neutral. That's a whole cluster of Price Targets ratcheting lower — $630 → $510 top, with the floor at $325.
The bull argument left standing: 88% gross margins, PEG of 0.28. Not a broken company — a hypergrowth story repricing to "prove it" mode. The r/r from here hinges on two things: Axon 3 delivery timeline, and whether brand dollars actually clear mobile in-app inventory at higher prices. If both hit, this is a double from $312. If Axon 3 slips, the bears get their number.
The bull case is broad and real: launch, orbital data centers, Starlink across consumer/enterprise/gov. LTM revenue $23B at 52% gross margins, still unprofitable (cost of doing business at this scale).
Supporting bids elsewhere: Wolfe Outperform at $175 (White House/FAA pushing launch cadence higher = volume tailwind). JPMorgan Overweight at $240, citing AI momentum and the Cursor acquisition (closed August). Add the $6B Grain Management spectrum licenses SpaceX and ASTS are circling — that's the D2D land grab, and it's a big one.
Risk on the tape: the second lockup release just hit. Recent softness is supply mechanics, not thesis breakage. Don't confuse the two.
Stifel's the only print, but it's a good one — $154 PT from $137, Buy maintained, and the thesis is finally about operating leverage, not just defense spending.
The quarter was a beat on every line that matters: ADJUSTED EPS $3.01 vs $2.31 consensus (+30.3%), revenue $1.88B (+6.8% vs est), and organic growth +5% — THE STRONGEST IN SIX QUARTERS. On-contract growth normalized to 9%. They raised the full-year guide on revenue, EBITDA, and EPS. That's not noise.
The real story is the multi-year margin trajectory. Management targeting ~11% operating margin by FY2030, 200bps above historical levels. If that lands, the re-rating math gets interesting — Stifel's anchoring FY28 at 11.5x, versus 14.6x current P/E and a 0.55 PEG. Cheap for a compounder with government backlog visibility.
"The company outlined a multi-year margin improvement plan targeting an operating margin of approximately 11% in fiscal year 2030, which would be more than 200 basis points above historical levels."
Bear case isn't hard to steelman: contract award delays in the quarter, and the AI-overhang on legacy systems integrators is real. But at this valuation, the market's pricing much of that in. The buyback optionality and the estimate revisions (3 analysts ticking numbers up) give the tape a bid. Light coverage day, but the signal is constructive — this is a name PMs should have on the watchlist for the margin inflection trade.
UBS says Paycom is "in the early phase of harvesting its transformation" — and put a $285 PT on it (from $205, Buy). That's the strongest bull call yet on the Beti-driven execution reset plus HCM late-cycle stabilization. The market's already half-convinced: stock +50% YTD, 11TH CONSECUTIVE REVENUE BEAT in Q2 (EPS $2.78 vs $2.38e, rev $531.2M vs $513.1e), and it still trades below its 3-year historical revenue multiple. At $242.10, this is a stone's throw from the $242.50 high.
The margin math is the real story. 520bps of adjusted EBITDA margin expansion over five years, 88% gross margin, capital return now exceeding FCF (vs essentially zero three years ago). UBS models 46.9% adjusted EBITDA margins by 2028 vs 43.1% in 2025 — 6% ABOVE STREET on 2028 EBITDA. At 25.5x P/E with a 0.83 PEG, the market's still pricing execution risk, not the harvest.
(Guggenheim and BTIG chimed in post-Q2 at $225/$230 — UBS is the outlier bull. Either they see something the tape doesn't or they're early to the re-rate. Given the 50% YTD run, the risk is "right but late.")
"Paycom is in the early phase of harvesting its transformation."
NVDA — FIRST-EVER QUANTIFIED FY2028 GUIDE LANDS AT ~+70% VS STREET +45-50%. At 14x 2027 EPS the market embeds a ~50% 2028 business decline that current orders don't corroborate. The offset: circular financing is now a priced factor, not a sell-side worry — the $35B Anthropic-Lambda deal closes the loop (NVDA → Lambda → Hut 8 → Anthropic → Lambda → NVDA), Barron's calls it 'most confusing yet,' stock goes weak. Rubin CPX (production 1Q27, 168GB HBM4/GPU, 1:1 with Rubin) lifts HBM content per paired inference system +58% — direct read-throughs to memory, optics, power.
TSM — Pricing power broadening: 10-15% hikes across all nodes, and Samsung's 4/5nm hikes corroborate scarcity is industry-wide, not just leading edge. COWOS FULLY SOLD OUT; LEAD TIMES RUN 52-78 WEEKS. TSMC routes ~$1.3B of HBM assembly through Intel Malaysia — 'others do back-end' is now real, not commentary. AI demand is extraordinary (compute 5x annually, system 50x by 2029 vs 2024; 30-40GW of data centers per year vs 5-6GW historically) — packaging, not wafer, stays the gating item. Section 301 tariffs land near Taiwan's negotiated ~15% — manageable, largely priced.
INTC — 14A defect density improvement is the FASTEST SINCE 22NM and ahead of internal target — the hardest foundry data point in three months. Caveat: yield curve doesn't equal committed customer, and Lip-Bu Tan's 'comfortable cash position' doesn't equal share. Add the Intel Malaysia CoWoS routing (~$1.3B HBM assembly; EMIB-T at roughly half CoWoS cost with mass production next year) and foundry optionality becomes the natural semis rotation spot in an AI de-grossing tape. SK hynix NOT using Intel for the HBM base die removes one bull leg — ecosystem lock-in, not manufacturing capability, is the real barrier.
AMD — MI355X in HUMAIN gives the non-NVIDIA rack a working production template: Ethernet fabric, no NVLink-style scale-up, actual traffic. Clearest AMD data-center win signal in a while. Question is margin, not capability.
AVGO — Near-term franchise intact — 2028 GPU designed for four of five frontier labs — but the NVDA-MediaTek tie-up is a credible longer-term volume-share risk to the custom XPU business. OpenAI Jalapeno (AI-assisted design-to-tapeout in ~9 months) structurally benefits custom ASIC vendors. The $100B-class debt stack reprices as global yields rise; that's the tape, not the thesis.
MRVL — Optics carries the raise while custom silicon waits for FY29. Stock sits at the 100-day MA ahead of the 10/6 analyst day; management says key news is saved. Asymmetric setup into deferred catalysts.
2454.TW — Market repriced MTK as NVDA-ecosystem equity, not a phone SoC company: NVDA subscribes $3.5B and Google $400M of the $3.9B convertible, stock limit-up +10% to NT$4,315. Rack-scale positioning with NVLink Fusion; CB proceeds may fund EMIB substrate prepayments. Verification points: 9/8 Singapore ECB listing and first NVHBM ASIC content.
CRDO — Into earnings tomorrow, expectations risk is the issue, not fundamentals. Strong results may already be in the price. HOLD reflects bar height, not thesis deterioration.
MU — Pricing is the story: Korea August DRAM ASP +1.8% MoM, FLASH ASP +63.3% MoM; HBM3E 36GB spot at $2,100 (4-5x LTA), HBM4 16-hi at $3,500. If you're not in an LTA, you're bidding for what's left. Rubin CPX lifts HBM content per paired inference system ~58%. The unmodeled risk: Taiwan union strike threat over profit sharing — NT$1.4T cumulative investment, 10k+ headcount, and any production hit collides with a DRAM shortage.
000660.KS — Custom HBM with compute in the base die claims LLM inference up to 5.15x; memory vendors move from spec follower to design partner. Reportedly NOT working with Intel on the base die — consolidates the TSMC-centered chain and pulls one bull leg from INTC. Rubin CPX feeds demand directly.
005930.KS — HBM5 spec sets the pace: 2x HBM4E performance, +20% per-watt, -20% thermal resistance, zHBM at 8x. LPDDR5X-PIM locks 2026 year-end to 2027 mass production at 3.8x. Foundry prices up 10-15% on 4LPX/5LPP and roughly 70% of memory capacity locked through 2031 — scarcity pricing, not mix shift.
SNDK — HBF is a new memory tier between HBM and NAND, not an HBM replacement. 512GB capacity, up to 3.072TB/s bandwidth, ~8-16x more capacity than HBM at similar cost. Best fit: MoE weights and massive KV caches. Software is the biggest hurdle.
009150.KS — AI passives scarcity spreads outward from HBM: SEMCO signs a KRW 1.0722T MLCC supply contract for CY2027 — 9.5% of annual revenue in one contract. FC-BGA utilization at 89%, server/DC demand >50% above capacity, ASP +18.7% YoY. MLCC price hikes (server X6S +10-20%, consumer X5R +25-30%) are mix optimization pushing out low-value demand.
011070.KS — Substrate utilization hit 94%; Package Solution sales +18%, op profit +94%. Capacity expansion in Gumi, Vietnam, Haiphong. Substrates are a hard gating item on AI chip volume.
3037.TW — Prosecutors raided over relabeled China-made PCBs as 'Made in Taiwan'; stock limit-down 10% to NT$999. Company says ABF substrates not implicated. AI substrate thesis contained if the clarification holds — but the headline is ugly.
6981.T — Japanese MLCC pricing follow-through is the tell. If Murata raises, SEMCO's move becomes a broad industry upcycle, not just mix optimization.
2408.TW / 7735.T — Nanya places ~$84M order with SCREEN, taking QTD equipment orders to ~$1.89B — ahead of Q2's ~$1.8B with a month left. YTD ~$4.4B. Memory capex accelerating.
ASMPT — CXMT HBM3E production directly benefits ASMPT as the TCB bonder supplier. Chinese HBM scaling stacks an equipment order book on top of the Korean cycle.
BESI.AS — Clear leader in two of three main markets, gaining share. Hybrid bonding and custom HBM both demand more advanced packaging equipment.
AEHR — Burn-in becomes structurally critical when one defect die scraps an expensive 3D module. The 126% up then 50% down round trip says positioning, not fundamentals.
6770.TW — PSMC is the qualified SiCap supplier for Intel EMIB; capacity plan raised from 3K wpm end-2026 to 8-10K wpm in 2H27. EMIB supply chain scaling ahead of demand corroborates the Intel packaging ramp.
LITE — LUMENTUM OWNS THE FIRST NPO SOCKET — and NPO is completely additive to CPO, so the laser gets paid twice. Ultra-high-power volume hits 2H27, customer placement 2028, first ELS orders on that calendar. Rubin CPX adds OSFP optical links for KV-cache networks between pools — incremental scale-out demand not in the old design.
COHR — Coherent sits on the same NPO/CPO scale-up — laser paid twice, scale-up is the bottleneck. Add 800VDC data centers launching 2027: SiC substrate/epi exposure maps to both COHR and WOLF. Multi-year content driver on both legs.
CIEN — Thursday's Q3 print tests whether the $7.7B backlog converts. Last quarter $1.57B, +40% YoY; FY26 guide ~$6.3B (~32% growth); Q3 guided ~$1.625B. CFO says: 'If we had more supply, we'd be able to sell more' — supply-constrained with visible demand. Three of four hyperscalers selected Ciena; hyperscaler concentration is the key risk.
CSCO — HUMAIN MI355X deployment: Silicon One Ethernet and 800G pluggables carry real 2026 revenue ahead of NPO/CPO scale-up. The non-NVIDIA AI stack has a live template. No NVLink-style scale-up fabric — backend network uses Silicon One. Real revenue story before the laser-heavy wave.
GLW — CPO/NPO PM fiber demand ~7,500-10,000 km globally this year, only ~1,500 km ordered domestically. No capacity shortage expected next year. PM fiber unlikely to gate the scale-up optics story.
POET — Breadcrumb map, not evidence: Lumilens ships under a multi-billion-dollar hyperscaler agreement, Lessengers has initial POs, Tier-1 ELS partner discussions circulate. If these triangulate, the story strengthens materially.
SOI.PA — Multi-year Photonics-SOI capacity reservations with fixed pricing and deposits — ~80% of 10+ agreements should sign within 1-2 weeks. FY Photonics-SOI revenue >$200M is 'absolutely only the floor'; UBS pegs ~95% market share. Stock up nearly 4x this year. Singapore decision window is 6-12 months; existing capacity covers two years, new fab needed ~2029.
ANET — Zhipu read-through positive: China AI buildout and Ethernet scale-out both broaden the networking TAM.
300308.SZ / 300502.SZ / 002281.SZ — Innolight, Eoptolink, Accelink all benefit from the Zhipu read-through: domestic accelerator deployments need high-speed optical interconnects. China's AI buildout is a real second demand pool.
3661.TW / 3443.TW — Alchip and Global Unichip ride the Zhipu custom-silicon read-through. Domestic accelerator and ASIC design work expands both pipelines.
3081.TW / 3363.TW / 3163.TW — LandMark (InP laser epi), FOCI (FAU/fiber), Browave (connectivity) sit in TSMC's CPO bottleneck map. CPO scaling constrained by lasers and fiber assembly more than silicon — direct supply-chain exposure.
4573.TW — GMT Global wins 800G/1.6T optical-module alignment orders; H1 revenue exceeded all of 2025; stock +~10%. Alignment is a gating step for high-speed modules.
6777.T — Optics test/instrument demand inflecting. An NVIDIA engineer echoes Fabrinet: messier optics need much more testing equipment to maximize yield. Tight specs and manufacturing complexity drive advanced optical instrument demand.
TER / KEYS / FORM / ATEYY — All named in the electro-optical test path. TSMC's packaging VP maps lasers, fiber, connectors, and full-stack testing as CPO constraints. Test complexity rises as optics get messier.
VRT — 2,300W-class CPX paired with Rubin at ~1:1 drives absolute power density higher while cost per token improves — cooling/power content per token grows. The binding constraint is deliverable power: 2027 North American AIDC demand ~35GW IT vs 16.5-23.4GW deliverable. Anything not in the interconnection queue by mid-2025 doesn't energize next year. Whoever compresses time-to-energization gets paid.
BE — Bloom is time-to-power infrastructure, not just a fuel-cell story. First Oracle deployment completed in 55 days vs 3-6 years for grid interconnection. A >10GW non-turbine power gap opens; 800VDC helps run more GPUs within existing power. If it scales, the bottleneck migrates to manufacturing throughput.
FCEL — Same non-turbine power gap, same 800VDC logic. Onsite generation separates campus construction from grid interconnection.
NBIS — Nebius signed at 3-4x its installed-base unit pricing within 18 months. ARR per GW spans $8.3B to $50B across four comparables. Power scarcity already monetized.
MOD — Hunterbrook confirms Google as a major hyperscale customer for Modine. Thermal-management content per MW grows; alt-data channels now price these wins faster. Validates the AI cooling thesis.
HUT — The Anthropic-Lambda $35B deal uses Hut 8's Texas data center — NVDA holds the lease on the data center. Hut 8 becomes a direct beneficiary of neocloud capex flowing to non-hyperscaler developers. Demand-driven story now, not bitcoin-macro.
SBE — SB Energy files S-1 with $439B contracted backlog, ~$430B from data centers. Hyperscaler capacity commitments shift off balance sheet; execution and financing risk land on third-party operators. New public AI-infrastructure vehicle.
ENR.DE — 800VDC transition favors grid-electrical franchises with LV/DC content. ENR screens cheaper than peers at ~12x 2028 EBIT. The Yates debate misses the point — CCGT capacity isn't the same as LV electrical content that's changing.
MPWR — Architecture-agnostic in the 800VDC power chain. At 1MW, 54V means ~18,500A vs 800V at ~1,250A. SiC/GaN plus vertical power delivery content grows from 2027.
VICR / NVTS / WOLF / ACLS / KLAC / ETN — The 800VDC supply chain sweep: VICR (48V + vertical power delivery), NVTS (pure-play GaN), WOLF (upstream SiC substrate/epi), ACLS (implant equipment for SiC), KLAC (metrology in SiC/GaN/HBM), ETN (LV/DC-capable electrical infrastructure). Multi-year content drivers.
2308.TW — Vera Rubin PSU capacitor issue is an R&D-phase quality fix, ~1-month rework cycle. High-power PSU failures get amplified; customers will harden multi-sourcing. Mainland suppliers move from second-source to core positions.
DELL — Earnings this week are the first report on the ghost-demand debate. AI second-tier capex commentary tests the data-center demand narrative. Fresh evidence point for the 'signed but not commenced' lease story.
2513.HK — Revenue missed (RMB953.9M vs RMB1.35B est.) but cloud revenue beat (RMB825.2M); gross margin 26.4% vs 50% a year ago. Forward signals matter more: August ARR exceeded 1H total; year-end guide to $2.4B from $1B. Inference cost per token fell 80%, MaaS token usage up 40x YTD, API ASP +101%, API gross margin from -0.4% to +24.6% — Jevons positive, not cannibalization. PRODUCTION INFERENCE ON ~100K DOMESTIC ACCELERATOR CARDS is the strongest public evidence Chinese chips crossed from pilot to production.
688256.SH / 688041.SH — Cambricon and Hygon ride the same Zhipu read-through: domestic accelerators in production-scale inference. End-to-end performance improved ~3x on the same hardware after an inference-engine rebuild. Volume ramp over the next 3-6 months is the catalyst.
BIDU — CFO gives the first clear China AI monetization timeline: AI profits and cash return 'soon' match search. If the next two quarters print, BIDU's re-rating space is the gap between search-decay discount and AI profitability.
BABA — T-Head expected to test CXMT HBM products as early as next year. China's AI silicon supply chain moves off the HBM embargo constraint. Strengthens the domestic compute stack.
ASX / AMKR — OSAT exposure to custom HBM and base-die assembly. AI packaging complexity expands the OSAT opportunity.
600176.SS — China Jushi September quotes push fiberglass cloth 7628 +15%, 2116/1080 +20%. Peers expected to follow. CCL supply chain cost inflation broadening.
600745.SS — Chinese court freezes Nexperia's Dutch assets ~$318M. Cross-border chip assets become hostages to judicial escalation. Wingtech carries the legal and political risk.
AAPL — Ternus officially takes CEO; Cook stays for China and tariffs. 9/10 launch is the first test. OpenAI calls the trade-secret case 'a mess of Apple's own making' — this is IP traceability in the agent era. Any folding-iPhone supply slip pushes 'new management + litigation distraction' into the multiple.
CRM — Customer behavior flips from tokenmaxxing to AI token budgeting. LLMs can't replace SoRs; Anthropic wants partnership, not replacement. Enterprise SoR rerating justified — CRM defends the data/workflow layer without defending the UI.
NOW — CRM read-through: enterprise SoR rerating justified. Channels show modest acceleration; AI tailwind looks gradual rather than a pulse.
GOOGL — TPU 8 splits the stack: 8t for training, 8i for inference. Not 'TPU replaces GPU' — NVIDIA still wins PyTorch/CUDA/multi-cloud. TPU 8i pushes memory to 288GB HBM (+50%), targeting inference and RL serving. Google's $400M in the MediaTek convertible locks custom silicon supply across a 10-year TPU horizon.
META — MTIA 300/400 integrates the NIC into the chip, following DeepSeek's multi-plane network blueprint. Meta internalizes scale-up networking. Reduces reliance on merchant NICs.
BYDDY — August sales +18% with record exports, offsetting domestic weakness. Beijing demands export price discipline ahead of EU tariff escalation. Overseas volume/price structure is the execution watch.
2317.TW / 2382.TW / 3231.TW — Section 301 tariffs likely land near Taiwan's negotiated ~15%, cushioned by >$300B US investment commitments. Foxconn's US expansion offsets tariff risk; Quanta and Wistron stay competitive in AI server assembly.
LRCX — Lam invests NT$9.8B (~US$310M) into its Taiwan subsidiary for advanced-node R&D and critical manufacturing. Deepens the Taiwan cluster moat. Incremental positive for WFE positioning.
All unverified — treat as color, not conviction.